Evidence map›Paper›PMID 42306306›Full record

ReviewFrontiers in cell and developmental biology2026

Involvement of the pyroptosis-HMGB1 axis in systemic diseases.

Ting Wang, Le Zhang, Jian Du, Qiuli Miao

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ting WangDepartment of General Surgery, Lequn Branch, The First Hospital of Jilin University, Changchun, China.
Le ZhangDepartment of Dermatology, The Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China.
Jian DuDepartment of Endocrinology and Spleen-Stomach Diseases, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Qiuli MiaoDepartment of Pharmacy, Lequn Branch, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyroptosis is a lytic form of regulated cell death driven by inflammasome activation and gasdermin-mediated membrane rupture, characterized by robust inflammatory amplification. High-mobility group box 1 (HMGB1), a multifunctional nuclear protein and damage-associated molecular pattern, has emerged as a central regulator within pyroptosis-associated pathologies. Acting both as a downstream alarmin released during pyroptotic cell death and as an upstream licensing factor for inflammasome activation and innate immune signaling, HMGB1 establishes a context-dependent feedforward loop that shapes tissue injury and immune responses. In infectious and inflammatory disorders, excessive HMGB1 release exacerbates immune dysregulation and organ damage, whereas in selected tumor settings, pyroptosis-associated HMGB1 contributes to immunogenic cell death and antitumor immunity. This review systematically summarizes the molecular mechanisms underlying HMGB1-regulated pyroptosis, including canonical and noncanonical inflammasome pathways, gasdermin execution, and crosstalk with other regulated cell death programs. We further integrate evidence implicating the pyroptosis-HMGB1 axis across systemic diseases involving the nervous, respiratory, digestive, circulatory, urinary, locomotor, endocrine, reproductive, and immune systems. Finally, we discuss emerging therapeutic strategies targeting this axis, highlighting opportunities and challenges for disease-specific and precision interventions.

Indexed as

gasderminsHMGB1inflammasomespyroptosisregulated cell deathsystemic diseases

Identifiers

PMID42306306
PMCPMC13265476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.